ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
How strong the interaction really are? Application of nanoITC in the analysis of the interaction between newly synthesized substances with potential anticancer activity and model carrier proteins.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Human Serum Albumin Nanoparticles as 3,6-Diazaphenothiazine Delivery System: Preparation and Interaction Studies.Molecules (Basel, Switzerland) · 2026Article
- Spectroscopic and calorimetric analysis of the interaction between human serum albumin and newly synthesized quinoline derivatives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Spectroscopic and calorimetric analysis of the interaction between 9-hydroxy-5-methyl-12Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work was to extend the existing knowledge of the interaction between newly synthetized substances with anticancer properties (5-methyl-12(H)-chino[3,4-b]-[1,4]-benzothiazine chloride (Salt1), 9-fluoro-5-alkyl-12(H)-quino[3,4-b][1,4]benzothiazine chloride (Salt2), and 9-amino-5-alkyl-12(H)-quino[3,4-b][1,4]benzothiazine chloride (Salt3) with model plasma carrier proteins. The thermodynamic profile of ligand-protein complexation and the contribution of bonds responsible for complex formation have been studied using calorimetry technique. The research has theoretical and experimental nature, but from a scientific point of view is novelty due to promising biological properties of Salt1, Salt2, and Salt3 and provide an important basis for further in vitro and in vivo studies. All measurements were conducted using nanoITC calorimeter (TA Instruments, New Castle, USA). The results were analyzed using Launch NanoAnalyze program (TA Instruments, New Castle, USA). Based on the obtained data, it is safe to consider the bonds within Salt1-HSA, Salt3-HSA, Salt1-AGP, Salt3-AGP, and Salt3-HGG complexes to be predominantly hydrophobic (ΔH > 0 and ΔS > 0) with K
Indexed as
Identifiers
39945815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.